Toulose, France Clinical Trials

A listing of Toulose, France clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 136 clinical trials
featured
A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Plus Pembrolizumab Versus Pemigatinib Alone Versus Standard of Care as First-Line Treatment for Metastatic or Unresectable Urothelial Carcinoma in Cisplatin-Ineligible Participants Whose Tumors Express FGFR3 Mutation or Rearrangement

The purpose of this study is to evaluate the safety and efficacy of pemigatinib plus pembrolizumab or pemigatinib alone versus the standard of care for participants with metastatic or unresectable urothelial carcinoma who are not eligible to receive cisplatin, are harboring FGFR3 mutation or rearrangement, and who have not received …

bladder carcinoma
bladder cancer
metastatic urothelial carcinoma
urothelial carcinoma
Institut Claudius Regaud Oncopole Toulouse
 (0.0 away) Contact site
  • 22 views
  • 14 Dec, 2020
  • +63 other locations
featured
A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy

The purpose of this study is to assess the efficacy of INCMGA00012 in participants with locally advanced or metastatic squamous carcinoma of the anal canal (SCAC) who have progressed after platinum-based chemotherapy.

measurable disease
platinum-based chemotherapy
chemotherapy regimen
Hospital General Universitari Vall D Hebron
 (154.0 away) Contact site
  • 62 views
  • 23 Nov, 2020
  • +23 other locations
featured
A Phase 2, Open-Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement

This is an open-label, monotherapy study of INCB054828 in subjects with myeloid/lymphoid neoplasms with FGFR1 rearrangement.  Subjects will receive a once daily (QD) dose of INCB054828 at 13.5 mg on a 2-week-on–therapy and 1-week-off–therapy schedule.  With Protocol Amendment 3, the administration schedule will be adjusted, and newly enrolled subjects will …

FGFR1
lymphoid malignancy
myeloid neoplasm
Institut Universitaire du Cancer de Toulouse - Oncopole
 (0.0 away) Contact site
  • 79 views
  • 14 Dec, 2020
  • +34 other locations
featured
A Phase 2, Open-Label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations

A Phase 2, Open-Label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations

urinary tract cancer
Research Center
 (0.3 away) Contact site
  • 1062 views
  • 08 Dec, 2020
  • +61 other locations
featured
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

The purpose of this study is to evaluate the efficacy and safety of pemigatinib in participants with previously treated locally advanced/metastatic or surgically unresectable solid tumor malignancies harboring activating FGFR mutations or translocations.  

malignancy
primary cancer
solid tumors
administration intravenous
measurable disease
Institut Claudius Regaud Oncopole Toulouse
 (0.0 away) Contact site
  • 46 views
  • 14 Dec, 2020
  • +61 other locations
A Clinical Study of to Confirm the Doses of Selexipag in Children With Pulmonary Arterial Hypertension

Selexipag is available for the treatment of pulmonary arterial hypertension (PAH) in adults in various countries. The efficacy of selexipag to delay disease progression was shown in a previous pivotal study conducted in 1156 adult patients with PAH. Given the similarities in the functional changes of PAH in children and …

hypertension
endothelin receptor antagonist
connective tissue disease
right heart catheterization
heart disease
HOSP ARNAUD DE VILLENEUVE - PAED DEPT (Montpellier)
 (116.2 away) Contact site
  • 34 views
  • 26 Apr, 2021
  • +92 other locations
Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

The purpose of this study is to evaluate the efficacy and safety of pemigatinib in participants with previously treated locally advanced/metastatic or surgically unresectable solid tumor malignancies harboring activating FGFR mutations or translocations.

Institut Universitaire du Cancer de Toulouse Oncopole
 (0.5 away) Contact site
  • 50 views
  • 01 Apr, 2021
  • +122 other locations
Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors

The overall objective of this study is to evaluate the efficacy and safety of cabozantinib as 2nd line treatment in subjects with unresectable, locally advanced or metastatic RCC with a clear-cell component, who progressed after prior Checkpoint Inhibitors (CPI) therapy with ipilimumab and nivolumab in combination or CPI combined with …

Institut Claudius R gaud
 (0.5 away) Contact site
  • 2 views
  • 05 Jun, 2021
  • +77 other locations
A Safety Efficacy and Systemic Exposure Study of CD5789 Cream in Adults and Adolescents With Lamellar Ichthyosis

This is a phase 2 randomized, multi-center, double-blind, vehicle controlled, 90 day, safety, efficacy, and systemic exposure study followed by a 90 day open-label extension of trifarotene cream in adults and adolescents with autosomal recessive ichthyosis with lamellar scale.

Hospital Clinic de Barcelona
 (157.2 away) Contact site
  • 101 views
  • 12 Mar, 2021
  • +34 other locations
Safety Tolerability Pharmacokinetics and Efficacy of EYP001a in Patients With Nonalcoholic Steatohepatitis (NASH)

The purpose of this study is to assess the effects of EYP001a with respect to safety, tolerability, pharmacokinetics and on markers of liver inflammation in patients with NASH

fibrosis
ENYO PHARMA Investigative site 0207
 (2.3 away) Contact site
  • 0 views
  • 24 Jan, 2021
  • +34 other locations